Check-Cap (NASDAQ:MBAI) Upgraded to Hold at Zacks Research

Check-Cap (NASDAQ:MBAI) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Tuesday, Zacks reports.

A number of other analysts have also recently commented on the stock. Northland Securities assumed coverage on shares of Check-Cap in a research report on Monday. They issued an “outperform” rating and a $10.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a report on Tuesday, July 21st. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Check-Cap has a consensus rating of “Hold” and an average price target of $10.00.

Check-Cap Stock Down 5.6%

Shares of NASDAQ MBAI opened at $3.54 on Tuesday. The company’s fifty day moving average is $7.04 and its 200-day moving average is $9.36. The stock has a market cap of $4.89 million, a price-to-earnings ratio of -0.25 and a beta of 0.67. Check-Cap has a twelve month low of $3.34 and a twelve month high of $27.44.

About Check-Cap

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.